Molecular analysis for ovarian cancer detection in patient-friendly samples
Rattachement africain : nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: High ovarian cancer mortality rates motivate the development of effective and patient-friendly diagnostics. Here, we explored the potential of molecular testing in patient-friendly samples for ovarian cancer detection. METHODS: Home-collected urine, cervicovaginal self-samples, and clinician-taken cervical scrapes were prospectively collected from 54 patients diagnosed with a highly suspicious ovarian mass (benign n = 25, malignant n = 29). All samples were tested for nine methylation markers, using quantitative methylation-specific PCRs that were verified on ovarian tissue samples, and compared to non-paired patient-friendly samples of 110 age-matched healthy controls. Copy number analysis was performed on a subset of urine samples of ovarian cancer patients by shallow whole-genome sequencing. RESULTS: Three methylation markers are significantly elevated in full void urine of ovarian cancer patients as compared to healthy controls (C2CD4D, P = 0.008; CDO1, P = 0.022; MAL, P = 0.008), of which two are also discriminatory in cervical scrapes (C2CD4D, P = 0.001; CDO1, P = 0.004). When comparing benign and malignant ovarian masses, GHSR shows significantly elevated methylation levels in the urine sediment of ovarian cancer patients (P = 0.024). Other methylation markers demonstrate comparably high methylation levels in benign and malignant ovarian masses. Cervicovaginal self-samples show no elevated methylation levels in patients with ovarian masses as compared to healthy controls. Copy number changes are identified in 4 out of 23 urine samples of ovarian cancer patients. CONCLUSIONS: Our study reveals increased methylation levels of ovarian cancer-associated genes and copy number aberrations in the urine of ovarian cancer patients. Our findings support continued research into urine biomarkers for ovarian cancer detection and highlight the importance of including benign ovarian masses in future studies to develop a clinically useful test.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Molecular analysis for ovarian cancer detection in patient-friendly samples
- Date Crossref
- 16/05/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Dutch Cancer Society pays non établi dans la noticeInstitution
-
Amsterdam University Medical Centers pays non établi dans la noticeÉtablissement de santé
-
Cancer Center Amsterdam pays non établi dans la noticeÉtablissement de santé
-
Vrije Universiteit Amsterdam Amsterdam UMC pays non établi dans la noticeUniversité ou école supérieure
-
The Netherlands Cancer Institute pays non établi dans la noticeÉtablissement de santé
-
Amsterdam Neuroscience pays non établi dans la noticeStructure de recherche
-
University of Amsterdam Amsterdam UMC pays non établi dans la noticeUniversité ou école supérieure
-
Antoni van Leeuwenhoek/Netherlands Cancer Institute pays non établi dans la noticeStructure de recherche
Dutch Cancer Society, Amsterdam University Medical Centers et Cancer Center Amsterdam, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.